Delcath Systems Inc
NASDAQ:DCTH
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
2.25
11.37
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one DCTH stock under the Base Case scenario is 17.26 USD. Compared to the current market price of 10.77 USD, Delcath Systems Inc is Undervalued by 38%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Delcath Systems Inc
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for DCTH cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Delcath Systems Inc
Balance Sheet Decomposition
Delcath Systems Inc
Current Assets | 31.4m |
Cash & Short-Term Investments | 19.9m |
Receivables | 3.7m |
Other Current Assets | 7.7m |
Non-Current Assets | 2.5m |
PP&E | 2.5m |
Current Liabilities | 12.3m |
Accounts Payable | 3.3m |
Accrued Liabilities | 4.5m |
Other Current Liabilities | 4.5m |
Non-Current Liabilities | 17.4m |
Other Non-Current Liabilities | 17.4m |
Earnings Waterfall
Delcath Systems Inc
Revenue
|
11.9m
USD
|
Cost of Revenue
|
-2.7m
USD
|
Gross Profit
|
9.2m
USD
|
Operating Expenses
|
-45.2m
USD
|
Operating Income
|
-36.1m
USD
|
Other Expenses
|
-20.3m
USD
|
Net Income
|
-56.3m
USD
|
Free Cash Flow Analysis
Delcath Systems Inc
USD | |
Free Cash Flow | USD |
In Q2 2024, Delcath Systems reported $7.8 million in revenue, driven by $6.6 million from the U.S. HEPZATO sales and $1.2 million from European CHEMOSAT sales. The company ended the quarter with 8 active treatment centers, forecasting 20 centers by the end of 2024. The average treatment rate exceeded expectations at just under 2 per month per center. Achieving New Technology Add-on Payment (NTAP) status for HEPZATO, Delcath expects to reach $10 million in quarterly U.S. revenue by Q4 2024, triggering $25 million in cash proceeds and potentially achieving cash flow positivity by Q1 2025.
What is Earnings Call?
DCTH Profitability Score
Profitability Due Diligence
Delcath Systems Inc's profitability score is 31/100. The higher the profitability score, the more profitable the company is.
Score
Delcath Systems Inc's profitability score is 31/100. The higher the profitability score, the more profitable the company is.
DCTH Solvency Score
Solvency Due Diligence
Delcath Systems Inc's solvency score is 39/100. The higher the solvency score, the more solvent the company is.
Score
Delcath Systems Inc's solvency score is 39/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
DCTH Price Targets Summary
Delcath Systems Inc
According to Wall Street analysts, the average 1-year price target for DCTH is 21.76 USD with a low forecast of 18.18 USD and a high forecast of 26.25 USD.
Dividends
Current shareholder yield for DCTH is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
DCTH Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Delcath Systems, Inc. is an oncology company, which focuses on the treatment of primary and metastatic liver cancers. The company is headquartered in New York City, New York and currently employs 45 full-time employees. The company went IPO on 2000-10-19. The firm's lead product candidate, the HEPZATO KIT (melphalan hydrochloride for injection/hepatic delivery system) is a drug/device combination product. HEPZATO KIT is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. In Europe, its commercial product is a medical device having the same device components as the HEZPATO KIT but without the melphalan hydrochloride, is designated as a Class III medical device, and is sold under the trade name CHEMOSAT Hepatic Delivery System for Melphalan (CHEMOSAT), where it is being used at various medical centers to treat a range of cancers of the liver. In the United States, HEPZATO KIT is considered a combination drug and device product. The firm's product administers concentrated regional chemotherapy to the liver.
Contact
IPO
Employees
Officers
The intrinsic value of one DCTH stock under the Base Case scenario is 17.26 USD.
Compared to the current market price of 10.77 USD, Delcath Systems Inc is Undervalued by 38%.